Adjuvant Formulations for Enhanced Immune Response
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer vaccines face challenges in stimulating effective Th1-biased immune responses due to the inability of traditional adjuvants like aluminum salts to promote the required cytokine environment for antigen presentation and T cell activation, particularly in therapeutic cancer vaccine development.
Innovation Solution
The development of adjuvant combinations packaged in nanoparticles or microparticles, such as porous silicon or lipid-based mRNA vaccines, which enhance cytokine production in antigen-presenting cells by stimulating interferon-β and tumor necrosis factor-α, thereby promoting antigen presentation and T cell activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional adjuvants like aluminum salts are used, then vaccine formulation is simple and cost-effective, but they fail to stimulate effective Th1-biased immune responses and cytokine production
Solution Approach 1:
The patent combines multiple adjuvant components (TLR ligands, STING agonists, cytokines) within nanoparticle or microparticle formulations to create composite adjuvant systems that simultaneously stimulate multiple immune pathways, achieving effective Th1-biased responses while maintaining formulation feasibility
Solution Approach 2:
The patent delivers specific adjuvant molecules to specific locations within the antigen-presenting cell (endosomes, cytoplasm, nucleus) using targeted particle delivery, ensuring that each adjuvant component acts at its optimal site to maximize immune stimulation while minimizing overall formulation complexity
2Reliability
If adjuvant molecules are packaged into nanoparticles or microparticles, then cytokine production and antigen presentation are enhanced, but manufacturing complexity increases
Solution Approach 1:
The patent designs nanoparticle and microparticle platforms that can accommodate multiple different adjuvant molecules and antigen types within a single formulation system, allowing the same delivery platform to serve multiple vaccine applications and simplifying manufacturing through platform standardization
Solution Approach 2:
The patent employs hierarchical packaging where adjuvant molecules are encapsulated within inner compartments (nanopores) that are themselves contained within larger microparticle structures, enabling controlled release and protecting sensitive molecules while maintaining manufacturability through modular assembly
3Reliability
If multiple adjuvant molecules are combined in particulate formulations, then immune activation is enhanced, but formulation stability becomes more difficult to maintain
Solution Approach 1:
The patent divides the multi-component adjuvant formulation into separate particulate units (nanoparticles or microparticles), with each particle containing one or more specific adjuvant molecules, preventing premature interactions between components while maintaining overall formulation stability through physical separation
Solution Approach 2:
The patent uses the nanoparticle or microparticle structure itself as an intermediary carrier that physically separates and protects sensitive adjuvant molecules from degradation, while controlling their release kinetics to maintain formulation stability during storage and delivery
Data Source
AI summary
The present invention provides a cell-based method for identification of an adjuvant and adjuvant combinations and a composition of a vaccine that includes the adjuvant and adjuvant combinations. The method comprises the steps: using an adjuvant or adjuvant combination to treat at least one type of antigen-presenting cells and measuring amount of at least one cytokine produced by the antigen-presenting cells.